Bernstein SocGen lowers Alnylam stock price target on valuation

Bernstein SocGen cut Alnylam's price target slightly to $447 from $448 while keeping an Outperform rating, citing strong U.S. momentum and Amvuttra beating consensus by 5%. The firm raised its FY2026 TTR estimate to $4,508 million, about 1% below management's guidance midpoint, and highlighted attractive valuation at under 7x EV/next-twelve-month sales with a PEG of 0.27. Separately, Alnylam reported Q1 2026 EPS of $1.99 versus $0.91 expected and revenue of $1.17 billion versus $1.12 billion expected, with quarterly net product revenue topping $1 billion for the first time.

Analysis

The market is still underestimating how much of ALNY’s re-rating is now driven by operating leverage rather than just top-line momentum. Once a rare-disease franchise crosses the billion-dollar quarterly revenue threshold, small incremental beats can translate into disproportionately better margin optics and cash generation, which is why the stock can absorb skepticism about geographic mix better than a typical launch story. The key second-order effect is that every proof point of durable U.S. share gain compresses the perceived risk premium around future launches, especially for a platform that investors had previously treated as execution- and reimbursement-fragile.

The bearish debate is really about sustainability versus one-quarter acceleration, and that matters because valuation will hinge on whether growth normalizes or compounds into 2026. If outside-U.S. launches keep outperforming while U.S. share keeps widening, the multiple can expand even if consensus EPS moves only modestly; if not, the stock becomes vulnerable to a fast de-rating because current expectations already imply a lot of future success. The market is also likely assigning too much binary weight to the competitor readthrough, when in practice class-level sentiment can move both names together even if near-term trader positioning tries to force a relative-value divergence.

For IONS, the setup is more interesting as a hedge than a standalone short. Any disappointment in ALNY’s durability would likely spill over into the broader RNA-therapeutics tape, but the reverse is also true: if ALNY keeps delivering, IONS can benefit from sector sympathy even without a comparable fundamental inflection. The consensus may be missing that “good enough” growth plus improving margins is often enough to sustain multiple expansion in a scarce-growth biotech, particularly when the company is still early in monetizing its platform outside the U.S.

Key Decisions for Investors

• Go long ALNY on pullbacks over the next 1-2 weeks; target a 3-6 month hold. Risk/reward is attractive if sequential revenue stays firm, because a modest multiple expansion can outrun consensus EPS revisions.
• Use IONS as a tactical pair leg: long ALNY / short IONS for 1-3 months if you expect the market to reward execution quality over platform sympathy. Stop if IONS starts trading as a clean sympathy beneficiary from broader RNA optimism.
• If already long ALNY, buy downside protection via 2-3 month puts financed with upside calls to express a 'good-but-not-perfect' thesis. This protects against the key risk: sequential growth disappointment despite strong annual growth.
• Add only on confirmation of follow-through in the next quarterly print; do not chase after a single beat. The setup improves materially if guidance is revised up again, but the stock is vulnerable if the midpoint stays ahead of visible quarterly cadence.
• For relative value, fade any sharp ALNY/IONS divergence in either direction; the better trade is the spread, not outright beta, because class sentiment can override single-name fundamentals in the short run.